pSivida (PSDV) Appoints New Director
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
pSivida Corp. (Nasdaq: PSDV) announced the appointment of Jay S. Duker, M.D, to the Company’s Board of Directors. Dr. Duker is the Director of the New England Eye Center and Professor and Chairman of Ophthalmology at the Tufts Medical Center and the Tufts University School of Medicine.
“Dr. Jay Duker is a recognized international expert in the treatment of diseases of the back of the eye,” said David J. Mazzo, Ph.D., Chairman of pSivida’s Board of Directors. “Dr. Duker’s unique combination of academic, research and clinical experience with ophthalmic disease will be a significant asset to pSivida. His contributions will be invaluable and I, along with the other Directors, look forward to working with him to advance our Company to the next level of success.”
As chairman of ophthalmology for Tufts Medical Center, Dr. Duker is responsible for managing the hospital's clinical ophthalmology practice. His role as chairman of ophthalmology for Tufts University School of Medicine encompasses leading the academic mission of the school, educating medical students, residents, fellows and practicing eye-care providers in ophthalmology and conducting ophthalmic research. As the Director of the New England Eye Center, he leads an academic, multi-specialty eye care group with 35 ophthalmologists and nearly 200 employees.
“Dr. Duker’s well-earned reputation among the ophthalmologist community combined with his scientific experience in eye diseases and corporate success bring a unique blend of science and business acumen to the pSivida board,” commented Nancy Lurker, President and Chief Executive Officer. “His addition further strengthens the Board’s capabilities and I’m excited to work alongside him to execute our business plan.”
In his clinical practice, Dr. Duker treats diseases of the posterior segment of the eye including age-related macular degeneration (AMD), diabetic retinopathy, posterior segment uveitis and retinal vascular diseases as well as rare retinal disorders. His principal research interests include retinal vascular disease, drug delivery to the eye, posterior uveitis and novel imaging techniques for the posterior segment. He has published nearly 200 peer-reviewed journal articles and authored four books on ophthalmology including a best-selling textbook. Dr. Duker serves on the editorial board of three ophthalmic journals. He is a graduate of Harvard University and Jefferson Medical College.
Dr. Duker is also a director of Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, and a co-founder and Director of Hemera Biosciences, a privately held company seeking to develop anti-complement gene based therapies for the treatment of dry and wet age related macular degeneration.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concordia International (CXRX) CEO to Step Down
- WPCS Int'l (WPCS) Names New Board Chairman
- Merck (MRK) Announces KEYTRUDA Phase 3 KEYNOTE-045 Met Primary Endpoint; Trial Stopped Early
Create E-mail Alert Related CategoriesManagement Changes, Management Comments
Related EntitiesTwitter, Dividend
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!